HC Wainwright Weighs in on ACADIA Pharmaceuticals Inc.’s FY2027 Earnings (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) – HC Wainwright raised their FY2027 EPS estimates for shares of ACADIA Pharmaceuticals in a note issued to investors on Tuesday, March 14th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will post earnings per share of $2.02 for the year, up from their previous forecast of $1.81. HC Wainwright has a “Buy” rating and a $28.00 price target on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is ($0.66) per share.

Several other equities research analysts also recently commented on ACAD. StockNews.com raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, December 1st. Cantor Fitzgerald upped their target price on ACADIA Pharmaceuticals from $28.00 to $33.00 and gave the stock an “overweight” rating in a research note on Tuesday. Royal Bank of Canada reissued an “outperform” rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Tuesday. Mizuho raised their price target on ACADIA Pharmaceuticals from $19.00 to $20.00 in a research note on Tuesday. Finally, Jefferies Financial Group lifted their price objective on ACADIA Pharmaceuticals from $10.00 to $15.00 in a research note on Tuesday. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $21.44.

ACADIA Pharmaceuticals Price Performance

ACAD opened at $19.85 on Wednesday. The firm’s fifty day moving average price is $19.08 and its two-hundred day moving average price is $17.09. The company has a market capitalization of $3.22 billion, a price-to-earnings ratio of -14.81 and a beta of 0.59. ACADIA Pharmaceuticals has a 1 year low of $12.24 and a 1 year high of $28.06.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) last released its quarterly earnings data on Monday, February 27th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.01). The company had revenue of $136.49 million during the quarter, compared to the consensus estimate of $135.18 million. ACADIA Pharmaceuticals had a negative net margin of 41.76% and a negative return on equity of 50.65%. The business’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.27) EPS.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in ACADIA Pharmaceuticals in the 2nd quarter valued at about $2,432,000. Nordea Investment Management AB raised its position in ACADIA Pharmaceuticals by 1.7% in the 2nd quarter. Nordea Investment Management AB now owns 630,080 shares of the biopharmaceutical company’s stock valued at $8,890,000 after purchasing an additional 10,555 shares in the last quarter. Bain Capital Life Sciences Investors LLC raised its position in ACADIA Pharmaceuticals by 1.7% in the 3rd quarter. Bain Capital Life Sciences Investors LLC now owns 610,523 shares of the biopharmaceutical company’s stock valued at $9,988,000 after purchasing an additional 10,000 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its position in ACADIA Pharmaceuticals by 1.1% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 200,032 shares of the biopharmaceutical company’s stock valued at $3,273,000 after purchasing an additional 2,117 shares in the last quarter. Finally, Cubist Systematic Strategies LLC raised its position in ACADIA Pharmaceuticals by 268.9% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 102,825 shares of the biopharmaceutical company’s stock valued at $1,682,000 after purchasing an additional 74,952 shares in the last quarter. Institutional investors and hedge funds own 92.79% of the company’s stock.

Insider Activity

In related news, Director Laura Brege sold 12,500 shares of the business’s stock in a transaction that occurred on Thursday, January 12th. The stock was sold at an average price of $18.25, for a total transaction of $228,125.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Stephen Davis sold 3,851 shares of the stock in a transaction dated Friday, February 24th. The stock was sold at an average price of $18.78, for a total transaction of $72,321.78. Following the transaction, the chief executive officer now owns 91,727 shares of the company’s stock, valued at approximately $1,722,633.06. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Laura Brege sold 12,500 shares of the stock in a transaction dated Thursday, January 12th. The stock was sold at an average price of $18.25, for a total value of $228,125.00. The disclosure for this sale can be found here. Insiders sold 23,567 shares of company stock worth $427,672 over the last three months. 28.40% of the stock is currently owned by corporate insiders.

ACADIA Pharmaceuticals Company Profile

(Get Rating)

ACADIA Pharmaceuticals, Inc is a biopharmaceutical company, which focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.